Cargando…
The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients
BACKGROUND: Previous studies have shown that Trimetazidine (TMZ) improves vascular endothelial function and reduces the inflammatory process progression. However, limited data have been available regarding its effects on myocardial fibrosis following ischemia and causing left ventricular dysfunction...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516770/ https://www.ncbi.nlm.nih.gov/pubmed/35538296 http://dx.doi.org/10.1007/s10557-022-07340-0 |
_version_ | 1785109198063796224 |
---|---|
author | El-khodary, Noha M. Ghoneim, Asser I. El-tayaar, Ahmed A. El-touny, Eman M. |
author_facet | El-khodary, Noha M. Ghoneim, Asser I. El-tayaar, Ahmed A. El-touny, Eman M. |
author_sort | El-khodary, Noha M. |
collection | PubMed |
description | BACKGROUND: Previous studies have shown that Trimetazidine (TMZ) improves vascular endothelial function and reduces the inflammatory process progression. However, limited data have been available regarding its effects on myocardial fibrosis following ischemia and causing left ventricular dysfunction. PURPOSE: To investigate the impact of TMZ adjuvant therapy for ischemic cardiomyopathy (ICM) on cardiac fibrosis, vascular endothelial function, inflammation, and myocardial functions. METHODS: This randomized, double-blind controlled clinical trial included 48 patients (aged 59.4 ± 9 years) with ICM who were randomly assigned to two groups: TMZ 35 mg twice daily and placebo in addition to conventional ICM medications. All patients received the tablets for 3 months. Both groups were then compared in terms of connective tissue growth factor (CTGF), endothelin-1 (ET-1), tumor necrosis factor-alpha (TNF-α), and some echocardiographic indices, weekly angina attacks and nitrate consumption before and after treatment. RESULTS: No significant differences between CTGF, ET-1, and TNF-α levels, in addition to some echocardiographic indices, were observed between both groups before treatment. After treatment, the TMZ group had significantly lower ET-1 than the placebo group, with both groups exhibiting a substantial decrease in TNF-α and CTGF. The TMZ group had lower mean ± SD levels for TNF-α and CTGF and showed significant improvement in echocardiographic indices and weekly angina attacks after treatment. CONCLUSION: Adjunctive TMZ therapy for ICM effectively improved vascular endothelial function and reduced inflammation. Furthermore, our exploratory findings may be used to provide new information on the potential effects of TMZ on myocardial fibrosis by downregulating CTGF. |
format | Online Article Text |
id | pubmed-10516770 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-105167702023-09-24 The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients El-khodary, Noha M. Ghoneim, Asser I. El-tayaar, Ahmed A. El-touny, Eman M. Cardiovasc Drugs Ther Original Article BACKGROUND: Previous studies have shown that Trimetazidine (TMZ) improves vascular endothelial function and reduces the inflammatory process progression. However, limited data have been available regarding its effects on myocardial fibrosis following ischemia and causing left ventricular dysfunction. PURPOSE: To investigate the impact of TMZ adjuvant therapy for ischemic cardiomyopathy (ICM) on cardiac fibrosis, vascular endothelial function, inflammation, and myocardial functions. METHODS: This randomized, double-blind controlled clinical trial included 48 patients (aged 59.4 ± 9 years) with ICM who were randomly assigned to two groups: TMZ 35 mg twice daily and placebo in addition to conventional ICM medications. All patients received the tablets for 3 months. Both groups were then compared in terms of connective tissue growth factor (CTGF), endothelin-1 (ET-1), tumor necrosis factor-alpha (TNF-α), and some echocardiographic indices, weekly angina attacks and nitrate consumption before and after treatment. RESULTS: No significant differences between CTGF, ET-1, and TNF-α levels, in addition to some echocardiographic indices, were observed between both groups before treatment. After treatment, the TMZ group had significantly lower ET-1 than the placebo group, with both groups exhibiting a substantial decrease in TNF-α and CTGF. The TMZ group had lower mean ± SD levels for TNF-α and CTGF and showed significant improvement in echocardiographic indices and weekly angina attacks after treatment. CONCLUSION: Adjunctive TMZ therapy for ICM effectively improved vascular endothelial function and reduced inflammation. Furthermore, our exploratory findings may be used to provide new information on the potential effects of TMZ on myocardial fibrosis by downregulating CTGF. Springer US 2022-05-10 2023 /pmc/articles/PMC10516770/ /pubmed/35538296 http://dx.doi.org/10.1007/s10557-022-07340-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article El-khodary, Noha M. Ghoneim, Asser I. El-tayaar, Ahmed A. El-touny, Eman M. The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients |
title | The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients |
title_full | The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients |
title_fullStr | The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients |
title_full_unstemmed | The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients |
title_short | The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients |
title_sort | impact of trimetazidine on cardiac fibrosis, inflammation, and function in ischemic cardiomyopathy patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516770/ https://www.ncbi.nlm.nih.gov/pubmed/35538296 http://dx.doi.org/10.1007/s10557-022-07340-0 |
work_keys_str_mv | AT elkhodarynoham theimpactoftrimetazidineoncardiacfibrosisinflammationandfunctioninischemiccardiomyopathypatients AT ghoneimasseri theimpactoftrimetazidineoncardiacfibrosisinflammationandfunctioninischemiccardiomyopathypatients AT eltayaarahmeda theimpactoftrimetazidineoncardiacfibrosisinflammationandfunctioninischemiccardiomyopathypatients AT eltounyemanm theimpactoftrimetazidineoncardiacfibrosisinflammationandfunctioninischemiccardiomyopathypatients AT elkhodarynoham impactoftrimetazidineoncardiacfibrosisinflammationandfunctioninischemiccardiomyopathypatients AT ghoneimasseri impactoftrimetazidineoncardiacfibrosisinflammationandfunctioninischemiccardiomyopathypatients AT eltayaarahmeda impactoftrimetazidineoncardiacfibrosisinflammationandfunctioninischemiccardiomyopathypatients AT eltounyemanm impactoftrimetazidineoncardiacfibrosisinflammationandfunctioninischemiccardiomyopathypatients |